<!DOCTYPE html><html><head><meta charSet="utf-8" class="next-head"/><title class="next-head">ALiEM Cards</title><meta name="viewport" content="initial-scale=1.0, width=device-width" class="next-head"/><meta charset="utf-8" class="next-head"/><meta http-equiv="x-ua-compatible" content="ie=edge" class="next-head"/><link rel="apple-touch-icon" sizes="180x180" href="/static/Favicons/apple-touch-icon.png" class="next-head"/><link rel="icon" type="image/png" href="/static/Favicons/favicon-32x32.png" sizes="32x32" class="next-head"/><link rel="icon" type="image/png" href="/static/Favicons/favicon-16x16.png" sizes="16x16" class="next-head"/><link rel="mask-icon" href="/static/Favicons/safari-pinned-tab.svg" color="#00b092" class="next-head"/><link rel="shortcut icon" href="/static/Favicons/favicon.ico" class="next-head"/><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Open+Sans" class="next-head"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/card.js" as="script"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_app.js" as="script"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_error.js" as="script"/><link rel="preload" href="/_next/static/runtime/webpack-89179faa512dd01fbb62.js" as="script"/><link rel="preload" href="/_next/static/chunks/commons.ce4c8f8c27f9b1d9e256.js" as="script"/><link rel="preload" href="/_next/static/chunks/styles.9b76ae77785496d5351a.js" as="script"/><link rel="preload" href="/_next/static/runtime/main-cfdfd101abde4b1d3f2a.js" as="script"/><link rel="stylesheet" href="/_next/static/css/commons.b3e9c004.chunk.css"/><link rel="stylesheet" href="/_next/static/css/styles.0fc85b66.chunk.css"/></head><body><div id="__next"><div data-reactroot=""><div><div class="header" role="banner"><div class="header__logo"><a href="/"><img src="/static/logo.svg"/></a></div><div class="header__nav-button"><button class="hamburger hamburger__squeeze"><span class="hamburger__box"><span class="hamburger__inner"></span></span></button></div><nav class="header__nav header__nav--closed" role="navigation"><ul><li><a href="/cards/">Cards</a></li><li><a href="/categories/">Categories</a></li><li><a href="/about/">About</a></li></ul></nav></div><div class="search"><div class="search__input" role="search"><input type="text" placeholder="Search" aria-label="Search for cards" value=""/></div></div></div><main class="content container" role="main"><article role="article"><h1>Cystitis and Pyelonephritis in Women</h1><div class="card"><div class="card__meta"><div><strong>Author: </strong>Michelle Lin, MD</div><div><strong>Updated:</strong> <!-- -->9/2/2011</div></div><div class="card__content"><h1 id="antibiotic-selection-for-cystitis-and-pyelonephritis-in-women">Antibiotic Selection for Cystitis and Pyelonephritis in Women</h1>
<p><em>2010 Infectious Disease Society of America (IDSA) and European Society for Microbiology and Infectious Diseases (ESMID) guidelines</em></p>
<p><strong>Target population</strong></p>
<ul>
<li>Acute, uncomplicated cystitis and pyelonephritis in women </li>
<li>Premenopausal, non-pregnant women without known urological abnormalities or co-morbidities (i.e. DM)</li>
</ul>
<h2 id="acute-uncomplicated-cystitis">Acute uncomplicated cystitis</h2>
<ol>
<li><span class="drug">Nitrofurantoin</span> (100 mg PO BID x 5 days)</li>
<li><strong><span class="drug">Trimethoprim</span>-sulfamethoxazole</strong> (1 DS tab PO BID x 3 days)<ul>
<li>Rising resistance rates</li>
<li>Only give if local antibiogram shows &lt;20% resistance</li>
</ul>
</li>
<li><span class="drug">Fosfomycin</span>(3 gm PO x 1)<ul>
<li>Slightly less efficiacy compared to standard short-course regimens </li>
</ul>
</li>
<li><span class="drug">Pivmecillinam</span> (400 mg PO BID x 3-7 days) <ul>
<li>Only available in Europe</li>
</ul>
</li>
<li><strong>Fluoroquinolones</strong> (3-day course of <span class="drug">ofloxacin</span>, <span class="drug">ciprofloxacin</span>, or <span class="drug">levofloxacin</span>) <ul>
<li>Avoid if possible to minimize selection of drug-resistant organisms</li>
</ul>
</li>
</ol>
<p><strong>Beta-lactams</strong> (3-7 day course of <span class="drug">amoxicillin-clavulanate</span>, <span class="drug">cefdinir</span>, <span class="drug">cefaclor</span>, <span class="drug">cefpodoxime-proxetil)</span></p>
<ul>
<li>Avoid if possible to minimize selection of drug-resistant organisms</li>
<li>Inferior efficacy compared with standard regimens</li>
<li><span class="drug">Cephalexin</span> less well studied</li>
</ul>
<h2 id="acute-pyelonephritis">Acute Pyelonephritis</h2>
<p>Urine analysis and urine culture should always be performed </p>
<p><span class="drug">Ciprofloxacin</span> (500 mg po BID x 7 days) +/- <span class="drug">ciprofloxacin</span> 400 mg IV x 1 dose
If <strong>&gt;10% resistance to fluoroquinolones</strong>, give 1-time IV dose:</p>
<ul>
<li><span class="drug">Ceftriaxone</span> 1 gm IV, or </li>
<li>An aminoglycoside </li>
</ul>
<p>If <strong>&lt;10% resistance rate,</strong> alternative oral fluoroquinolone outpatient dosing options:</p>
<ul>
<li><span class="drug">Ciprofloxacin</span> XR 1000 mg po daily x 7 days, or</li>
<li><span class="drug">Levofloxacin</span> 750 mg po daily x 5 days </li>
</ul>
<p><span class="drug">Trimethoprim-sulfamethoxazole</span> (1 tab DS PO BID x 14 days)
1.  If resistance rate unknown, give 1-time dose of <span class="drug">ceftriaxone</span> 1 gm IV or aminoglycoside first</p>
<p><strong>Beta-lactams</strong> (10-14 day course)
1.  Because of less efficacy, give 1-time dose of <span class="drug">ceftriaxone</span> 1 gm IV or aminoglycoside first </p>
<h2 id="references">References</h2>
<ul>
<li>Gupta K et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the IDSA and the ESMID. Clin Infect Dis. 2011; 52(5). [<a href="https://www.ncbi.nlm.nih.gov/pubmed/10589881">PubMed</a>]</li>
</ul>
</div></div></article></main><div class="footer" role="contentinfo"><div class="container"><div class="row footer__cc"><div class="footer__cc-image"><a rel="license" href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><img alt="creative-commons" src="/static/by-nc-nd.svg"/></a></div><div class="footer__cc-text">This work is licensed under a<!-- --> <a rel="license" href="http://creativecommons.org/licenses/by-nc-nd/3.0/">Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License</a>.</div></div><div class="row footer__links"><div><a href="/contact/">Contact</a></div><div><a href="/contact/">Get Involved</a></div><div><a href="/about/">About</a></div></div><div class="row row--centered"><div class="container footer__disclaimer">ALiEM Cards content is intended for use by healthcare professionals. Users of this site should exercise their own clinical judgment as to the reliability and accuracy of its information. Non-healthcare-professionals who use this site do so at their own risk. Content on this site should not be construed as medical advice. Users should always confer with medical profoessionals regarding decisions about medications, evaluations and other medical treatments.</div></div></div></div></div></div><script>__NEXT_DATA__ = {"props":{"pageProps":{"card":{"slug":"cystitis-pyelonephritis-women","title":"Cystitis and Pyelonephritis in Women","authors":["Michelle Lin, MD"],"categories":[{"slug":"infectious-disease","name":"Infectious Disease"},{"slug":"genitourinary","name":"Genitourinary"}],"created":"2011/09/02","updated":null,"body":"\n# Antibiotic Selection for Cystitis and Pyelonephritis in Women\n\n_2010 Infectious Disease Society of America (IDSA) and European Society for Microbiology and Infectious Diseases (ESMID) guidelines_\n\n**Target population**\n\n- Acute, uncomplicated cystitis and pyelonephritis in women \n- Premenopausal, non-pregnant women without known urological abnormalities or co-morbidities (i.e. DM)\n\n## Acute uncomplicated cystitis\n\n1. \u003cspan class=\"drug\"\u003eNitrofurantoin\u003c/span\u003e (100 mg PO BID x 5 days)\n2. **\u003cspan class=\"drug\"\u003eTrimethoprim\u003c/span\u003e-sulfamethoxazole** (1 DS tab PO BID x 3 days)\n   - Rising resistance rates\n   - Only give if local antibiogram shows \u0026lt;20% resistance\n3. \u003cspan class=\"drug\"\u003eFosfomycin\u003c/span\u003e(3 gm PO x 1)\n   - Slightly less efficiacy compared to standard short-course regimens \n4. \u003cspan class=\"drug\"\u003ePivmecillinam\u003c/span\u003e (400 mg PO BID x 3-7 days) \n   - Only available in Europe\n5. **Fluoroquinolones** (3-day course of \u003cspan class=\"drug\"\u003eofloxacin\u003c/span\u003e, \u003cspan class=\"drug\"\u003eciprofloxacin\u003c/span\u003e, or \u003cspan class=\"drug\"\u003elevofloxacin\u003c/span\u003e) \n   - Avoid if possible to minimize selection of drug-resistant organisms\n\n**Beta-lactams** (3-7 day course of \u003cspan class=\"drug\"\u003eamoxicillin-clavulanate\u003c/span\u003e, \u003cspan class=\"drug\"\u003ecefdinir\u003c/span\u003e, \u003cspan class=\"drug\"\u003ecefaclor\u003c/span\u003e, \u003cspan class=\"drug\"\u003ecefpodoxime-proxetil)\u003c/span\u003e\n\n- Avoid if possible to minimize selection of drug-resistant organisms\n- Inferior efficacy compared with standard regimens\n- \u003cspan class=\"drug\"\u003eCephalexin\u003c/span\u003e less well studied\n\n## Acute Pyelonephritis\n\nUrine analysis and urine culture should always be performed \n\n\u003cspan class=\"drug\"\u003eCiprofloxacin\u003c/span\u003e (500 mg po BID x 7 days) +/- \u003cspan class=\"drug\"\u003eciprofloxacin\u003c/span\u003e 400 mg IV x 1 dose\nIf **\u003e10% resistance to fluoroquinolones**, give 1-time IV dose:\n\n- \u003cspan class=\"drug\"\u003eCeftriaxone\u003c/span\u003e 1 gm IV, or \n- An aminoglycoside \n\nIf **\u0026lt;10% resistance rate,** alternative oral fluoroquinolone outpatient dosing options:\n\n- \u003cspan class=\"drug\"\u003eCiprofloxacin\u003c/span\u003e XR 1000 mg po daily x 7 days, or\n- \u003cspan class=\"drug\"\u003eLevofloxacin\u003c/span\u003e 750 mg po daily x 5 days \n\n\u003cspan class=\"drug\"\u003eTrimethoprim-sulfamethoxazole\u003c/span\u003e (1 tab DS PO BID x 14 days)\n1\\.  If resistance rate unknown, give 1-time dose of \u003cspan class=\"drug\"\u003eceftriaxone\u003c/span\u003e 1 gm IV or aminoglycoside first\n\n**Beta-lactams** (10-14 day course)\n1\\.  Because of less efficacy, give 1-time dose of \u003cspan class=\"drug\"\u003eceftriaxone\u003c/span\u003e 1 gm IV or aminoglycoside first \n\n## References\n\n- Gupta K et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the IDSA and the ESMID. Clin Infect Dis. 2011; 52(5). [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/10589881)]\n"}}},"page":"/card","pathname":"/card","query":{"slug":"cystitis-pyelonephritis-women"},"buildId":"1~ee3OFOv6kXxZUoU_eCb","nextExport":true};__NEXT_LOADED_PAGES__=[];__NEXT_REGISTER_PAGE=function(r,f){__NEXT_LOADED_PAGES__.push([r, f])}</script><script async="" id="__NEXT_PAGE__/card" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/card.js"></script><script async="" id="__NEXT_PAGE__/_app" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_app.js"></script><script async="" id="__NEXT_PAGE__/_error" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_error.js"></script><script src="/_next/static/runtime/webpack-89179faa512dd01fbb62.js" async=""></script><script src="/_next/static/chunks/commons.ce4c8f8c27f9b1d9e256.js" async=""></script><script src="/_next/static/chunks/styles.9b76ae77785496d5351a.js" async=""></script><script src="/_next/static/runtime/main-cfdfd101abde4b1d3f2a.js" async=""></script></body></html>